Preliminary data from the pilot study suggests repeat administration with Inno-305 is well tolerated and immune response can be elicited following three vaccinations.
In the study conducted at the Memorial Sloan-Kettering Cancer Center, patients receive six vaccinations over 12 weeks with Inno-305 along with the immune adjuvant Montanide. Preliminary data indicates that a CD4 response was seen in five of six patients and a CD8 response was seen in patients with HLA-A0201.
Inno-305, also known as WT1 heteroclitic peptide immunotherapy, is unique among WT1 peptide cancer immunotherapeutics because of its ability to stimulate both CD8 and CD4 T-cells.
Steve Kelly, president and CEO of Innovive Pharmaceuticals, said: “We believe Inno-305 has the potential to elicit robust immune responses in patients with several serious cancer types including AML, CML, myelodysplastic syndrome, non small cell lung cancer and mesothelioma.”